Citius Oncology announced a distribution agreement with Uniphar, a Dublin-based international healthcare services company, to provide access to denileukin diftitox (Lymphir) across Western and Eastern ...
H2H will evaluate the efficacy and safety of rondecabtagene autoleucel (ronde-cel) versus Investigator’s choice of approved ...
MedPage Today on MSN
Prior Ibrutinib May Improve CAR-T Efficacy in Rare Lymphoma
Findings could be practice changing if proven prospectively, experts say ...
In 2024, Professor Sebastian Kobold's research group at LMU University Hospital had already shown that the metabolite ...
Brexucabtagene autoleucel approval marked a significant advancement in MCL treatment, achieving a 62% complete remission rate in resistant or relapsed patients. Prognostic tools like the Ki-67 index ...
Why most eligible lymphoma patients miss CAR T: experts urge stronger academic-community handoffs, clearer protocols, and ...
MB-105, a CD5-targeted CAR-T cell therapy, is being evaluated in a phase 2 trial for relapsed or refractory CD5-positive T-cell lymphoma. The trial, led by Dr. Swaminathan P. Iyer, will assess ...
The FDA has removed R/R PCNSL from a Limitations of Use section on the CAR-T product’s label based on positive findings from ...
In the treatment of non-Hodgkin lymphoma with CD19 chimeric antigen receptor (CAR) T-cell therapy, baseline kidney function did not appear to be associated with an increased risk of developing acute ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results